[FLEP therapy for advanced and recurrent XXXX ].

@entity1 @entity3136 @entity882 @entity1431 @entity356 @entity1487 @entity1209
The FLEP regimen ( @entity1487 , LV, ETP and CDDP) is a combination chemotherapy administered regionally and systemically for the control of both local and disseminated disease in intra- and extra-abdominal regions in @entity1 with advanced and recurrent @entity356 . Sixty-one @entity1 with advanced and recurrent @entity356 were entered into this study. The treatment regimen consisted of @entity1487 at 370 mg/m2 (days 1 to 5, i.v. 24 h); LV at a dose of 30 mg (days 1 to 5, i.v. bolus); and ETP and CDDP each at 70 mg/m2 (days 7 and 21, ia 2 h). This regimen was repeated every four weeks. The overall response rate was 36.1% (22/61) and the 50% and median survival times were 10.23 and 11.80 months, respectively. The adverse events were Grade 3/4 @entity1431 (18.0%), Grade 3/4 @entity882 (4.9%), Grade 3 @entity1209 (3.3%) and Grade 3 @entity3136 (1.6%). Of the 17 NAC @entity1 , the six curability B @entity1 showed a statistically higher survival rate than the curability C and unresected @entity1 . Based on the encouraging response rate and the improvement in prognosis, we recommend the FLEP regimen for @entity1 with primary @entity356 . Neoadjuvant chemotherapy using the FLEP regimen should be performed with curative resection as an objective.
